Research analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research note issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Trading Down 5.5 %
Shares of NASDAQ:PULM opened at $2.05 on Monday. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $2.75. The business has a 50-day moving average price of $2.10 and a two-hundred day moving average price of $1.98. The stock has a market capitalization of $7.49 million, a P/E ratio of -0.85 and a beta of 0.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The business had revenue of $1.55 million during the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Warren Buffett Stocks to Buy Now
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
